SPRITAM Drug Patent Profile

When do Spritam patents expire, and what generic alternatives are available?

Spritam is a drug marketed by Aprecia Pharms and is included in one NDA. There are three patents protecting this drug.

This drug has twenty patent family members in nine countries.

The generic ingredient in SPRITAM is levetiracetam. There are thirty-five drug master file entries for this compound. Eighty-seven suppliers are listed for this compound. Additional details are available on the levetiracetam profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Spritam

A generic version of SPRITAM was approved as levetiracetam by MYLAN on November 4^th, 2008.

Summary for SPRITAM

International Patents:	20
US Patents:	3
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for SPRITAM

US Patents and Regulatory Information for SPRITAM

SPRITAM is protected by five US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Aprecia Pharms	SPRITAM	levetiracetam	TABLET, FOR SUSPENSION;ORAL	207958-004	Jul 31, 2015		DISCN	Yes	No			Y
Aprecia Pharms	SPRITAM	levetiracetam	TABLET, FOR SUSPENSION;ORAL	207958-001	Jul 31, 2015		RX	Yes	No
Aprecia Pharms	SPRITAM	levetiracetam	TABLET, FOR SUSPENSION;ORAL	207958-002	Jul 31, 2015		RX	Yes	Yes			Y
Aprecia Pharms	SPRITAM	levetiracetam	TABLET, FOR SUSPENSION;ORAL	207958-003	Jul 31, 2015		DISCN	Yes	No			Y
Aprecia Pharms	SPRITAM	levetiracetam	TABLET, FOR SUSPENSION;ORAL	207958-003	Jul 31, 2015		DISCN	Yes	No			Y
Aprecia Pharms	SPRITAM	levetiracetam	TABLET, FOR SUSPENSION;ORAL	207958-004	Jul 31, 2015		DISCN	Yes	No

International Patents for SPRITAM

See the table below for patents covering SPRITAM around the world.

Country	Patent Number	Title	Estimated Expiration
Mexico	365513	FORMA DE DOSIFICACION DE DISPERSION RAPIDA QUE CONTIENE LEVETIRACETAM. (RAPID DISPERSE DOSAGE FORM CONTAINING LEVETIRACETAM.)
Japan	2017071626	レベチラセタムを含む急速に分散する剤形 (RAPID DISPERSE DOSAGE FORM COMPRISING LEVETIRACETAM)
Australia	6331498
Australia	2014228990	Rapid disperse dosage form containing levetiracetam
Spain	2318869
European Patent Office	2968994	FORME PHARMACEUTIQUE À DISPERSION RAPIDE CONTENANT DU LÉVÉTIRACÉTAM (RAPID DISPERSE DOSAGE FORM CONTAINING LEVETIRACETAM)

Supplementary Protection Certificates for SPRITAM

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0162036	2000C/032	Belgium		PRODUCT NAME: LEVETIRACETAM; NAT. REGISTRATION NO/DATE: EU/1/00/146/001 20000929; FIRST REGISTRATION: CH 55297 20000329
0162036	C300028	Netherlands		PRODUCT NAME: LEVETIRACETAM; REGISTRATION NO/DATE: EU/1/00/146/001 - EU/1/00/146/026 20000929

Investment Scenario and Fundamentals Analysis for SPRITAM (Levetiracetam)

Last updated: February 20, 2026

What is SPRITAM and how does it fit within the epilepsy treatment market?

SPRITAM is a prescription tablet formulation of levetiracetam, approved by the FDA in 2015 under the brand name SPRITAM (levetiracetam). Developed by UCB for epilepsy management, it offers a dissolvable tablet version of a widely prescribed anti-epileptic drug (AED). Its primary competitors are other branded and generic AEDs such as Keppra (oral solution and tablets) and generic levetiracetam products.

What are the key market characteristics and growth drivers?

• Market Size: The global epilepsy treatment market was valued at approximately $4.9 billion in 2022. It is expected to grow at a compound annual growth rate (CAGR) of 4.2% through 2030 (Grand View Research, 2022).
• Patient Population: An estimated 50 million people worldwide have epilepsy, with about 30% resistant to first-line therapies.
• Treatment Paradigm: The shift towards patient-friendly formulations, such as dissolvables and films, influences product demand.
• Regulatory status: FDA-approved since 2015; UCB holds exclusive rights to the formulation, limiting direct competition unless generics enter.

What are the competitive advantages and limitations of SPRITAM?

Advantages:

• Differentiability: A rapid-dissolving form designed to improve adherence, particularly in pediatric and geriatric populations.
• Branding: UCB has marketed SPRITAM mainly as a convenience alternative to tablet forms.
• Patent protections: While some patents have expired, formulation-specific patents and exclusivity periods protect market share.

Limitations:

• Cost: Typically priced higher than generic levetiracetam, which can limit utilization.
• Manufacturing complexity: The proprietary print technology increases manufacturing costs.
• Market penetration: Sales have been modest, partly due to reimbursement challenges and clinician familiarity with traditional tablets.

How do patent dynamics and regulatory landscape impact investment?

• Patent expirations: Original formulations and device patents began expiring around 2020-2022, opening opportunities for generic versions.
• Legal challenges: UCB has faced patent challenges related to the spray-dried particle technology and dissolution characteristics.
• Regulatory pathways: The FDA’s 505(b)(2) pathway facilitated accelerated approval but also created pathways for generics to challenge exclusivity.

What are the financial considerations?

• Sales performance: UCB reported $36 million in SPRITAM sales in 2021, with stagnant growth.
• Cost structure: Manufacturing costs are higher than standard levetiracetam, impacting margin compression as generics enter.
• Market share: Estimated to be less than 10% of total levetiracetam prescriptions in the U.S.

What are the investment risks and opportunities?

Risks:

• Market saturation with generics diminishes premium for branded formulations.
• Regulatory and patent challenges may lead to patent invalidation or lower exclusivity periods.
• Competitive pressure from new formulations and alternative delivery systems.

Opportunities:

• Enhanced formulations that improve patient adherence could regain market share.
• Expansion into emerging markets with high epilepsy prevalence.
• Strategic licensing or partnership deals for formulation patents.

What is the outlook for SPRITAM’s future?

The outlook depends on patent litigation outcomes, new formulations, and shifts in prescribing behaviors. Even with limited market share growth, SPRITAM's niche role and patient preference for dissolvables present niche opportunities. However, price competition from generics remains a significant hurdle.

Key Takeaways

• SPRITAM is a branded, dissolvable version of levetiracetam with niche advantages related to patient compliance.
• The drug operates in a market characterized by high generic penetration, exerting downward pressure on revenues.
• Patent protections have eroded, raising risks of generic competition.
• Growth prospects hinge on formulation innovation, market expansion, and legal/ patent evolution.
• Investment risks include pricing erosion, patent litigation, and slow adoption rates; opportunities relate to differentiated formulations and emerging markets.

FAQs

1. How does SPRITAM compare price-wise to generic levetiracetam?
SPRITAM costs significantly more, often two to three times the price of generics, which limits its formulary placement and prescription volume.

2. What patent protections remain for SPRITAM?
Patent expiry began around 2020, with some patent extensions and formulation-specific patents still in force, but these are increasingly challenged in courts and through generic applications.

3. What are the main barriers for SPRITAM's growth?
Cost, limited awareness among physicians, and generic competition remain primary barriers.

4. Are there any regulatory risks for SPRITAM?
Yes, patent challenges and potential for generic entrants via ANDA filings pose risks to exclusivity.

5. Can SPRITAM penetrate emerging markets?
Yes, in regions with high epilepsy prevalence and limited access to branded formulations, SPRITAM’s patient adherence benefits could drive demand, but pricing and local regulatory approval are hurdles.

---

References

[1] Grand View Research. (2022). Epilepsy Treatment Market Size, Share & Trends Analysis Report.
[2] UCB Annual Report. (2022). Financial and R&D reporting.
[3] U.S. Food & Drug Administration. (2015). FDA approves first dissolvable tablet for epilepsy.